Reply to the Letter to the Editor 'Risk-adapted modulation through de-intensification of cancer treatments : an ESMO classification' by Hannoun-Levi et al
| Errataetall: |
CommentOn: Ann Oncol. 2022 Jul;33(7):702-712. - PMID 35550723 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 33(2022), 12 vom: 15. Dez., Seite 1331-1333 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Franzoi, M A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.12.2022 Date Revised 11.12.2022 published: Print-Electronic CommentOn: Ann Oncol. 2022 Jul;33(7):702-712. - PMID 35550723 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2022.09.154 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346323371 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346323371 | ||
| 003 | DE-627 | ||
| 005 | 20231226031149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2022.09.154 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346323371 | ||
| 035 | |a (NLM)36115609 | ||
| 035 | |a (PII)S0923-7534(22)04145-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franzoi, M A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reply to the Letter to the Editor 'Risk-adapted modulation through de-intensification of cancer treatments |b an ESMO classification' by Hannoun-Levi et al |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.12.2022 | ||
| 500 | |a Date Revised 11.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Ann Oncol. 2022 Jul;33(7):702-712. - PMID 35550723 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 700 | 1 | |a Trapani, D |e verfasserin |4 aut | |
| 700 | 1 | |a Jezdic, S |e verfasserin |4 aut | |
| 700 | 1 | |a Regan, M M |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Andre, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 33(2022), 12 vom: 15. Dez., Seite 1331-1333 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:12 |g day:15 |g month:12 |g pages:1331-1333 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2022.09.154 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 12 |b 15 |c 12 |h 1331-1333 | ||